LECANEMAB-IRMB (LEQEMBI)

LECANEMAB-IRMB (LEQEBMI) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease.

Indication:

  • Mild cognitive impairment due to Alzheimer's disease

  • Mild Alzheimer's disease dementia, with confirmed amyloid pathology

Injection Duration:

A circular icon with a blue arrow forming a loop around a large black number 1, with the word 'HOUR' below, indicating a 1-hour time cycle, and a leaf and flame graphic on the left side of the circle.

Frequency:

  • Every two weeks. (At least 14 days apart)